Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

345M-1

Sigma-Aldrich

Uroplakin III (AU-1) Mouse Monoclonal Antibody

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
NACRES:
NA.41

pochodzenie biologiczne

mouse

Poziom jakości

100
500

białko sprzężone

unconjugated

forma przeciwciała

culture supernatant

rodzaj przeciwciała

primary antibodies

klon

AU-1, monoclonal

opis

For In Vitro Diagnostic Use in Select Regions (See Chart)

Postać

buffered aqueous solution

reaktywność gatunkowa

human

opakowanie

vial of 0.1 mL concentrate (345M-14)
vial of 0.5 mL concentrate (345M-15)
bottle of 1.0 mL predilute (345M-17)
vial of 1.0 mL concentrate (345M-16)
bottle of 7.0 mL predilute (345M-18)

producent / nazwa handlowa

Cell Marque

metody

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

izotyp

IgG1

kontrola

bladder

Warunki transportu

wet ice

temp. przechowywania

2-8°C

wizualizacja

membranous

informacje o genach

human ... UPK3A(7380)

Opis ogólny

Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes of 16-nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35 metastatic (66%) urothelial carcinomas, whereas many non-urothelial carcinomas were UPIII-negative. The authors concluded that UPIII should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary site. Recently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression was absent after malignant transformation. Thus, UP expression might reflect the malignant potential of urothelial cancer cells as well as being cytodifferential markers of urothelial cells. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower tumor grades, that lack of UPIII expression in urothelial tumors of the upper urinary tract was associated with much higher rates of metastases, and that 5-year specific survival was much worse for UPIII negative tumors (54%) than for UPIII positive tumors (100%). Apparently UPIII expression is a better indicator of the malignant potential of the tumour than the grade of the tumour.

Associated products: Thrombomodulin, CK7, CK20

Jakość


IVD

IVD

IVD

RUO

Powiązanie

Uroplakin III Positive Control Slides, Product No. 345S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Postać fizyczna

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Uwaga dotycząca przygotowania

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Inne uwagi

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informacje prawne

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

Nie możesz znaleźć właściwego produktu?  

Wypróbuj nasz Narzędzie selektora produktów.

Kod klasy składowania

12 - Non Combustible Liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

R A Badalament et al.
The Journal of urology, 144(4), 859-863 (1990-10-01)
A total of 50 patients with primary transitional cell carcinoma of the upper urinary tract underwent deoxyribonucleic acid ploidy characterization by flow cytometric analysis of paraffin embedded specimens. The primary tumor was diploid in 29 patients (58%) and aneuploid in
M C Hall et al.
Urology, 52(4), 594-601 (1998-10-08)
To review a large single-center experience of patients treated for upper tract transitional cell carcinoma (TCC) with extended follow-up in order to identify patterns of recurrence, assess patient outcomes, and determine the impact of traditional prognostic factors. We reviewed 252
Sanjay Logani et al.
The American journal of surgical pathology, 27(11), 1434-1441 (2003-10-25)
Ovarian tumors containing cells with transitional cell morphology are recognized in the 1999 World Health Organization classification of ovarian tumors and include benign Brenner tumor, borderline and malignant Brenner tumor, and transitional cell carcinoma. Recent immunohistochemical investigations have reached conflicting
Yukihiro Ohtsuka et al.
BJU international, 97(6), 1322-1326 (2006-05-12)
To investigate the association between the expression of uroplakin III (UPIII) and the prognosis of patients with urothelial carcinoma of the upper urinary tract, as uroplakins are urothelium-specific markers of terminal urothelial differentiation. Clinicopathological and follow-up data from 71 patients
Jonathon Olsburgh et al.
The Journal of pathology, 199(1), 41-49 (2002-12-11)
The uroplakins are widely regarded as urothelium-specific markers of terminal urothelial cytodifferentiation. This study investigated the expression of the four uroplakin genes, UPIa, UPIb, UPII and UPIII, in a wide range of normal human tissues to determine tissue specificity and

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej